The Inventors developed conditions allowing to efficiently detect differences in cardiomyocytes relaxation phases associated with increased cardiomyocytes stiffness. They used a
library of patient-specific
human induced pluripotent stem cells (hiPSC) either from healthy donors or carrying mutations (i.e., MYH7 and BRAF mutations) associated with
hypertrophic cardiomyopathy, a condition typically associated with impaired
diastolic function as well as an increase in cardiomyocytes passive stiffness. They performed a
high throughput screening on hiPSC-derived cardiac cells to identify microRNAs capable of modifying the relaxation rates of cardiomyocytes. In particular, they set up a large-scale
functional genomics using miRNAs screening. All identified miRNAs were tested for their
impact on cardiac
cells movement and
calcium transient. miRNAs with the highest
impact were in particular tested on ECTs and changes in
diastolic function, were measured and compared to the results obtained at the
cell level. They manipulated the most interesting ‘hits’ in 3D models using similar readouts as in primary assays. They tested the
impact of the positive ‘hits’ in
mechanical models (developed during the exploratory part) and establish physiological and biochemical mechanisms of action of the identified key proteins. They finally identified two promising miRNAs that could be used for improving striated myocytes relaxation and, more generally, to alleviate symptoms related to striated
muscle stiffness, in particular in the context of
heart failure with a preserved
ejection fraction (HFpEF).